Cabergoline and MK-2866 Interaction
Cabergoline and MK-2866 have a synergistic interaction with 55% confidence. MK-2866 supports hormonal recovery from suppression caused by Cabergoline. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life. Both compounds affect the gonads, so monitoring these systems is recommended.
Compound Profiles
Cabergoline
Dopamine Agonist | Prolactin Management
Cabergoline exerts its effects by acting as a potent agonist at dopamine D2 receptors on lactotroph cells in the anterior pituitary gland. Prolactin secretion is tonically inhibited by hypothalamic dopamine acting on these D2 receptors, and cabergoline mimics this inhibitory signal with high affinity and prolonged duration.
View full profileMK-2866
Selective Androgen Receptor Modulator | Muscle Wasting Research
MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.
View full profileCombined Organ Load
Frequently Asked Questions
Can I take Cabergoline with MK-2866?
Yes, Cabergoline and MK-2866 can generally be taken together. MK-2866 supports hormonal recovery from suppression caused by Cabergoline. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life.
Is Cabergoline and MK-2866 safe together?
Based on pharmacological analysis, this combination is considered synergistic. No critical safety flags identified for this pair.
What are the interactions between Cabergoline and MK-2866?
MK-2866 supports hormonal recovery from suppression caused by Cabergoline. Standard protocol — begin PCT after the suppressive compound has cleared based on its half-life. This assessment has 55% confidence and is inferred from pharmacological mechanism analysis.
How should I time Cabergoline and MK-2866?
Cabergoline has a half-life of ~63-69 hours and MK-2866 has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.